Pharmacogenomic and clinical data link non-pharmacokinetic metabolic dysregulation to drug side effect pathogenesis.

7e ), whereas overexpressed pathways were preferentially depleted as effective nutrient supplements (19% depletion, binomial P =0.14), although the relationships did not reach statistical significance for given sample sizes available.

also in 111,027 other papers

This overlap between DISLoDGED pathways and non-pharmacokinetic side effect susceptibility altering genes was highly significant (joint hypergeometric tests, P -value 2.2 × 10 −11 , see Supplementary Note 2 for calculation).

also in 132,142 other papers